Literature DB >> 29941433

Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor.

Lydia Zhang1, Michael Tamilia2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29941433      PMCID： PMC6019336          DOI： 10.1503/cmaj.171319

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  9 in total

1.  Hyperglycemic emergencies in adults.

Authors:  Jeannette Goguen; Jeremy Gilbert
Journal:  Can J Diabetes       Date:  2013-03-26       Impact factor: 4.190

2.  Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.

Authors:  Michael Fralick; Sebastian Schneeweiss; Elisabetta Patorno
Journal:  N Engl J Med       Date:  2017-06-08       Impact factor: 91.245

3.  Euglycaemic diabetic ketoacidosis.

Authors:  J F Munro; I W Campbell; A C McCuish; L J Duncan
Journal:  Br Med J       Date:  1973-06-09

Review 4.  SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.

Authors:  Ronald M Goldenberg; Lori D Berard; Alice Y Y Cheng; Jeremy D Gilbert; Subodh Verma; Vincent C Woo; Jean-François Yale
Journal:  Clin Ther       Date:  2016-12       Impact factor: 3.393

Review 5.  SGLT2 Inhibitors May Predispose to Ketoacidosis.

Authors:  Simeon I Taylor; Jenny E Blau; Kristina I Rother
Journal:  J Clin Endocrinol Metab       Date:  2015-06-18       Impact factor: 5.958

Review 6.  Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

Authors:  Norm Rosenthal; Gary Meininger; Kirk Ways; David Polidori; Mehul Desai; Rong Qiu; Maria Alba; Frank Vercruysse; Dainius Balis; Wayne Shaw; Robert Edwards; Scott Bull; Nicholas Di Prospero; Sue Sha; Paul Rothenberg; William Canovatchel; Keith Demarest
Journal:  Ann N Y Acad Sci       Date:  2015-08-25       Impact factor: 5.691

Review 7.  SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.

Authors:  Kelly R Burke; Christine A Schumacher; Spencer E Harpe
Journal:  Pharmacotherapy       Date:  2017-01-16       Impact factor: 4.705

Review 8.  Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight.

Authors:  Awadhesh Kumar Singh
Journal:  Indian J Endocrinol Metab       Date:  2015 Nov-Dec

9.  Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.

Authors:  Wataru Ogawa; Kazuhiko Sakaguchi
Journal:  J Diabetes Investig       Date:  2015-09-06       Impact factor: 4.232
  9 in total
  4 in total

1.  Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis.

Authors:  Siddhartha Dutta; Tarun Kumar; Surjit Singh; Sneha Ambwani; Jaykaran Charan; Shoban B Varthya
Journal:  J Family Med Prim Care       Date:  2022-03-10

2.  Nephrology Consultation for Severe SGLT2 Inhibitor-Induced Ketoacidosis in Type 2 Diabetes: Case Report.

Authors:  Felice Nappi; Antonietta La Verde; Giovanni Carfora; Carlo Garofalo; Michele Provenzano; Ferdinando Carlo Sasso; Luca De Nicola
Journal:  Medicina (Kaunas)       Date:  2019-08-10       Impact factor: 2.430

3.  Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Who Underwent Surgery for Pancreatic Carcinoma: A Case Report.

Authors:  Xiaoqian Luo; Ran Ji; Weina Lu; Hong Zhu; Libin Li; Jun Hu
Journal:  Front Surg       Date:  2022-02-23

Review 4.  Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review.

Authors:  Adeboye Olakunle Bamgboye; Isaac Oluwadamilare Oni; Andrew Collier
Journal:  Eur J Clin Pharmacol       Date:  2020-11-26       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.